- Home
- Companies
- Zymeworks Inc
- Products
- Zanidatamab - Bispecific Antibody
Zanidatamab - Bispecific Antibody
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.
Zanidatamab has been granted Breakthrough Therapy designation for biliary tract cancer from the FDA, as well as two Fast Track designations, one for previously treated or recurrent HER2-positive biliary tract cancer and another for first-line gastroesophageal adenocarcinoma in combination with standard of care chemotherapy. Zanidatamab also received Orphan Drug designation for the treatment of biliary tract and gastric cancers in the United States and for gastric cancer in the European Union.
- Biliary Tract Cancers
- Breast Cancer
- Gastroesophageal Adenocarcinomas
- Colorectal Cancer
- HER2-Expressing Cancers